Targeting KRAS Mutant Non Small Cell Lung Cancer with Adagrasib: Current Status and Future Questions

Time: 3:50 pm
day: Day One


  • History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C
  • Clinical progress of KRAS G12C inhibitors (e.g. adagrasib) and treatment of patients with NSCLC
  • Future questions and directions for targeting KRAS G12C, including biomarkers and combination strategies